Objectives: This study aims to investigate the prognostic value of the CHA2DS2-VA score in patients with permanent atrial fibrillation (AF). Patients and methods: Between January 20223 and June 2023, a total of 917 patients with permanent AF (446 males, 471 females; mean age: 70.29.7 years; range, 27 to 89 years) were retrospectively analyzed. The patients were divided into two groups based on their CHA2DS2-VA scores: high-risk (score ≥2, n=743) and low-risk (score <2, n=174). Data on one-year all-cause mortality were collected through follow-ups and interviews. Results: In the univariate analysis, CHA2DS2-VA score, age, sex, systolic blood pressure (SBP), left ventricular ejection fraction (LVEF), chronic obstructive pulmonary disease (COPD), chronic kidney disease, hemoglobin, neutrophil, and lymphocyte counts were found to be significant predictors of mortality. Multivariate analysis revealed that only age, sex, SBP, COPD, LVEF, and hemoglobin were independent predictors. There was a significant relationship between CHA2DS2-VA score and one-year all-cause mortality (p=0.002). Conclusion: Our study results showed that the CHA2DS2-VA score was associated with one-year all-cause mortality in AF patients, but it was not an independent predictor when evaluated with all parameters affecting mortality. In the management of AF patients, the CHA2DS2-VA score may be useful not only in determining oral anticoagulation strategy, but also in the approach of clinicians to AF patients, considering that it may be a predictor of mortality.
